Press Releases Shanghai Henlius Biotech, Inc.

Equities

2696

CNE100003N76

Delayed Hong Kong S.E. Other stock markets 03:18:15 2024-05-10 am EDT			5-day change	1st Jan Change
17.12 ^HKD	+0.94%		+3.13%	+23.17%

May. 06	Henlius Biotech Gets US FDA Clearance for Phase 3 Trial of Gastric Cancer Combination Therapy	MT
May. 06	Shanghai Henlius Biotech, Inc. Announces Application for the Phase 3 Clinical Trial of HLX22 in Combination with Trastuzumab and Chemotherapy as the First-Line Treatment of HER2 Positive Advanced Gastric Cancer Approved by the United States Food and Drug Administration	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Henlius maintained a positive momentum of development in Q1 2024, with impressive performances by core products	Apr. 30	AQ
Shanghai Henlius Biotech, Inc. - IND Application for the Clinical Trial of Novel Anti-TIGIT Fc Fusion Protein HLX53 in Combination with HANSIZHUANG Plus HANBEITAI Approved by NMPA	Apr. 18	AQ
Henlius Releases 2023 ESG Report: Pursuing Sustainable Development with Patient-centricity	Apr. 17	PR
Henlius Forecasts Profit in 2023: Achieving first full year of profitability, and ushering in a new phase of high-quality development	Mar. 04	PR
Henlius Adalimumab Biosimilar Received sNDA Acceptance Notification from the NMPA	Mar. 01	AQ
Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene	Jan. 12	AQ
Triple Negative Breast Cancer Pipeline, FDA Approvals, Clinical Trials Assessment, Companies 2023 \| Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., and others.	Dec. 05	AQ
Henlius Xuhui Facility Passes Colombian GMP Inspection for HANLIKANG	Nov. 29	AQ
Anaplastic Thyroid Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	Nov. 23	AQ
Henlius Deepens Collaboration with Intas to bring Henlius Novel anti-PD-1 mAb Serplulimab to Europe and India	23-10-30	AQ
Henlius Announces NMPA Approvals of Two ADC Candidates for IND	23-10-30	AQ
Shanghai Henlius Biotech, Inc. - First Patient Dosed for MRCT Phase 3 Study on First-Line LS-SCLC of Henlius Anti-PD-1 mAb Serplulimab in Europe	23-10-26	AQ
Henlius Biotech, Inc. - Results from the Preclinical Study of HLX43, a Potential FIC PD-L1-Targeting ADC Released at 2023 ESMO	23-10-25	AQ
Henlius Xuhui Facility Passes PIC/S Member ANVISA GMP Inspection for HANLIKANG and HANQUYOU	23-10-23	AQ
Henlius Xuhui Facility Passes GMP Inspection for HANSIZHUANG by PIC/S Member BPOM	23-10-12	AQ
Henlius Novel Anti-PD-1 mAb HANSIZHUANG approved for the Treatment of ESCC	23-09-25	AQ
Henlius Expands Collaboration with KGbio to Develop, Commercialize and Supply Henlius novel anti-PD-1 mAb HANSIZHUANG in MENA	23-09-13	AQ
Henlius Biotech, Inc. - HANQUYOU Marks 3rd Anniversary with Brilliant Achievements	23-07-28	AQ
Henlius Holds its 1st Overseas Scientific Advisory Board Meeting of 2023	23-06-28	PR
Advanced Gastric Carcinoma Pipeline Assessment of Active Pipeline Assets Segmented by Stage, Product Type, Route of Administration, and Molecule Type	23-03-14	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Shanghai Henlius Biotech, Inc.

Equities

2696

CNE100003N76

Press Releases

Filters